KPTI
Karyopharm Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.79
+1.13%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
Market Cap
$40.60M
MomentumView details →
1D Return
+1.13%
YTD Return
−75.41%
RSI (14)
28.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
Market Cap
$40.60M
RSI (14)
28.1
MomentumView details →
1D Return
+1.13%
YTD Return
−75.41%
SummaryUpdated Jun 1, 2026
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a commercial-stage pharmaceutical company founded in 2008 and headquartered in Newton, Massachusetts. The company went public in 2013 and specializes in developing and commercializing a novel class of cancer drugs called Selective Inhibitor of Nuclear Export (SINE) compounds. Karyopharm's lead product, XPOVIO (selinexor), is currently approved for multiple myeloma and diffuse large B-cell lymphoma, with the company advancing an ambitious pipeline of three Phase 3 trials targeting additional cancer indications including myelofibrosis and endometrial cancer.
Similar companies
Latest newsMore news →
Karyopharm Therapeutics submitted a supplemental New Drug Application to the U.S. FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for patients with myelofibrosis.4d agoKaryopharm Therapeutics reported a Q2 2026 loss of $2.32 per share, missing the Zacks Consensus Estimate of a loss of $1.53, and compared to a loss of $4.32 per share a year ago.22d ago